ITCI - Intra-Cellular Therapies

-

$undefined

N/A

(N/A)

Intra-Cellular Therapies NASDAQ:ITCI Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

Location: 430 E 29th St, New York, 10016-8367, US | Website: www.intracellulartherapies.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

7.105B

Cash

1.023B

Avg Qtr Burn

-15.23M

Short % of Float

2.34%

Insider Ownership

2.34%

Institutional Own.

97.16%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Caplyta (Lumateperone) Details
Bipolar depression, Mental health

Approved

Quarterly sales

Caplyta (Lumateperone) Details
Schizophrenia, Mental health

Approved

Quarterly sales

Caplyta (Lumateperone) Details
Mental health, Major depressive disorder

sNDA

Submission

Phase 2

Data readout

Lenrispodun (ITI-214) (PDE1 inhibitor) Details
Heart disease, Parkinson's disease

Phase 2

Data readout

Phase 1

Data readout

ITI-333 Details
Sleeping disorder, Bipolar depression, Opioid use disorder

Phase 1

Update

LAI (lumateperone long acting injection) Details
Mental health, Schizophrenia, Major depressive disorder, Bipolar disease

Phase 1

Initiation